Clinical properties
|
Total
|
p16 expression (n/%)
|
---|
Negative (%)
|
Positive (%)
|
P value
|
---|
Gender
| | | | |
Male
|
103
|
85(66.4 %)
|
18(60.0 %)
|
0.507
|
Female
|
55
|
43(33.6 %)
|
12(40.0 %)
|
Age (mean)
| | | | |
< 58
|
85
|
60(48.0 %)
|
13(50.0 %)
|
0.853
|
≥ 58
|
67
|
65(52.0 %)
|
13(50.0 %)
|
Histopathological grade
| | | | |
Well
|
38
|
34(27.2 %)
|
4(13.3 %)
|
0.268
|
Moderate
|
97
|
76(60.8 %)
|
21(70.0 %)
|
Poor
|
20
|
15(12.0 %)
|
5(16.7 %)
|
Invasion depth
| | | | |
T1-T2
|
78
|
63(53.8 %)
|
15(51.7 %)
|
0.838
|
T3-T4
|
68
|
54(46.2 %)
|
14(48.3 %)
|
Lymphatic invasion
| | | | |
N0
|
66
|
48(42.5 %)
|
18(64.3 %)
|
0.038
|
N1-N3
|
75
|
65(57.5 %)
|
10(35.7 %)
|
TNM Staging
| | | | |
I/II
|
76
|
59(60.8 %)
|
17(77.3 %)
|
0.147
|
III/IV
|
43
|
38(39.2 %)
|
5(22.7 %)
|
HPV infection
| | | | |
Negative
|
66
|
52(53.1 %)
|
14(60.9 %)
|
0.499
|
Positive
|
55
|
46(46.9 %)
|
9(39.1 %)
|
-
P < 0.05 indicates a significant association among the variables